A recent study published in the New England Journal of Medicine highlights a new potential treatment for type 1 diabetes using zimislecel, an allogeneic stem cell-derived islet-cell therapy. The study involved 14 participants, with 12 receiving full doses showing significant improvements; most notably, 10 achieved insulin independence after one year. However, challenges such as neutropenia and two fatalities raise caution. The study suggests this therapy may offer an alternative to current insulin treatments, with Vertex Pharmaceuticals planning an FDA application for 2026 if results remain favorable.
According to their testing, the results of a new stem cell-derived islet-cell therapy for type 1 diabetes could lead to significant improvements in patients' lives.
A groundbreaking study showed promising results using zimislecel therapy, where most participants achieved insulin independence a year after treatment.
Collection
[
|
...
]